C. Michael Gibson/LinkedIn
Nov 8, 2025, 11:18
C. Michael Gibson and Atul Verma on OCEAN Trial: Rivaroxaban VS Aspirin in AF
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Atul Verma and I discuss the OCEAN trial: In AF patients after successful catheter ablation, is long-term anticoagulation with low-dose rivaroxaban more effective than aspirin in preventing stroke or systemic embolism?
AHA25 View it here.”
Stay updated with Hemostasis Today.
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH
-
Jan 8, 2026, 03:47Wolfgang Miesbach on Fernando Corrales-Medina’s Team’s Latest Cross-Sectional Study on Haemophilia
-
Jan 8, 2026, 03:28Rick Matthews: Powerful Perspective from Erin and the NBCA Team